Keywords: Phytopharm, Cogane, Parkinson's disease, Ph II

Phytopharm goes into free-fall, as Cogane fails in key Parkinson's trial

Article | 18 February 2013

UK drug developer Phytopharm (LSE: PYM) saw its shares plummet 80% to 2 pence (on February 18), after the company announced disappointing results ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Phytopharm

Go to company listing

Related Drugs

Cogane

Go to drug listing